Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, et al; SPARCL Investigators. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011;68:1245 1251. doi: 210. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, B jot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, et al; Treat Stroke to Target Investigators. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J 211. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, DariusH,LewisBS,OphuisTO,JukemaJW,etal;IMPROVE-ITInvestigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 2397. doi: 10.1056/NEJMoa1410489 212. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in pa- tients with cardiovascular disease. N Engl J Med. 2017;376:1713 1722. 213. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097 2107. doi: 214. Chiavaroli L, Nishi SK, Khan TA, Braunstein CR, Glenn AJ, Mejia SB, Raheli D, Kahleov H, Salas-Salvad J, Jenkins DJA, et al. Portfolio di- etary pattern and cardiovascular disease: a systematic review and meta- analysis of controlled trials. Prog Cardiovasc Dis. 2018;61:43 53. doi: 215. Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, Erbey J, Sugano DS. 